The Scripps Research Institute

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Dartmouth College

International Aids Vaccine Initiative

Cornell University

Andrew B Ward

Ian A Wilson

Dennis R Burton

Linling He

Jiang Zhu

Leopold Kong

Hannah Turner

Natalia De Val

Barney S Graham

Michael Gordon Joyce

Masaru Kanekiyo

Jason Scott McLellan

Hadi M Yassine

Kizzmekia S Corbett

Nianshuang Wang

Robert Kirchdoerfer

Christopher Cottrell

Jesper Pallesen

John S Moore

C Richter King

Yu Feng

Andre Marozsan

Simon Hoffenberg

Richard Wyatt

Michael P Caulfield

Rogier W Sanders

Javier Guenaga

Viktoriya Dubrovskaya

Albert Cupo

Rogier Sanders

P J Klasse

Jean-Philippe Julien

Karen Tran

Shailendra Kumar

Lars Hangartner

Jidnyasa Ingale

Natalia De Val Alda

Matteo Bianchi

Hansi Dean

Per Johan Klasse

Michael Caulfield

Jean-Phillippe Julien

John Moore

Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.

Prefusion coronavirus spike proteins and their use

The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.

HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion envelope conformations

Nucleic acids encoding HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations

Provided herein are methods for mapping antibody binding to an immunogen, comprising: immunizing a subject with an immunogen and obtaining sera from the immunized subject at multiple time intervals following immunization, wherein the sera comprises antibodies that are used to form one or more immune complexes with the immunogen; isolating the one or more immune complexes formed by the serum derived antibodies bound to the immunogen; imaging, by electron microscopy, the one or more immune complexes in each of the time intervals, to obtain structural images formed between the immunogen and serum antibodies; determining, from the plurality of structural images, immunogen-antibody binding site for each of the immune complexes obtained at the plurality of time intervals; mapping immunogen-antibody binding by measuring differences in structural images obtained at different time intervals to determine immunogen-antibody binding over multiple time intervals.

Epitope mapping method

HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations

The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

Soluble HIV-1 envelope glycoprotein trimers

The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron microscopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.

HIV-1 envelope glycoprotein

Growing community of inventors

San Diego, CA, United States of America

Andrew B Ward